Supporting Market Access to Essential Medicines in Europe
.png?width=109&height=108&name=Pharma%20(2).png)
Our client is a leading pharmaceutical manufacturer in Asia, specializing in anesthetics, analgesics, and narcotics. With a strong presence in global markets, the company aimed to introduce a key product to Europe where access to similar treatments remains limited. However, entering the European market required navigating complex regulatory requirements, including obtaining an EU GMP license to ensure compliance with stringent quality and safety standards.
Challenge
Approach
Result
Challenge
Regulatory & compliance challenges
To bring their product to European patients, the company needed to secure an EU GMP license, conduct audits to demonstrate compliance, and establish a solid regulatory strategy.
In addition, they were responsible for compiling and submitting a complete dossier, managing communication with regulatory authorities, and implementing laboratory method transfer to support retesting and Qualified Person (QP) batch release.
Approach
Ensuring a smooth regulatory pathway
QbD Group provided comprehensive regulatory and quality support to to guide the company toward market entry. Our approach included:
- Conducting audits at the API and finished product manufacturing sites to support the QP declaration.
- Developing a robust regulatory strategy, compiling the Common Technical Document (CTD) and eCTD for submission.
- Managing communication with regulatory authorities and addressing deficiency letters to streamline approval.
- Facilitating laboratory method transfer to ensure smooth retesting and QP batch release processes.
Result
Progressing toward market authorization
While the project is still ongoing, significant milestones have been achieved:
- Submission of key regulatory documentation to support the EU GMP licensing process.
- Active engagement with competent authorities to address regulatory feedback and refine submission materials.
- Future pharmacovigilance support planned to ensure ongoing compliance and patient safety.
The ultimate goal remains securing timely Market Authorization Approval enabling the company to introduce its product in Europe and expand patient access to essential treatments.
Get in touch
Looking for expert regulatory support to enter the European market?
Contact us today to discuss your project and explore how we can support your success.